Cargando…

Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study

BACKGROUND/AIMS: This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC). METHODS: A prospective, observational, multicenter study was conducted over 56 weeks in adult patients with moderately to severely act...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Seung Yong, Park, Soo Jung, Kim, Young, Im, Jong Pil, Kim, Hyo Jong, Lee, Kang-Moon, Kim, Ji Won, Jung, Sung-Ae, Lee, Jun, Kang, Sang-Bum, Shin, Sung Jae, Kim, Eun Sun, Kim, You Sun, Kim, Tae Oh, Kim, Hyun-Soo, Park, Dong Il, Kim, Hyung Kil, Kim, Eun Soo, Kim, Young-Ho, Kim, Do Hyun, Teng, Dennis, Kim, Jong-Hwa, Kim, Wonyong, Choi, Chang Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344242/
https://www.ncbi.nlm.nih.gov/pubmed/34289648
http://dx.doi.org/10.5217/ir.2021.00049
_version_ 1784761176975998976
author Shin, Seung Yong
Park, Soo Jung
Kim, Young
Im, Jong Pil
Kim, Hyo Jong
Lee, Kang-Moon
Kim, Ji Won
Jung, Sung-Ae
Lee, Jun
Kang, Sang-Bum
Shin, Sung Jae
Kim, Eun Sun
Kim, You Sun
Kim, Tae Oh
Kim, Hyun-Soo
Park, Dong Il
Kim, Hyung Kil
Kim, Eun Soo
Kim, Young-Ho
Kim, Do Hyun
Teng, Dennis
Kim, Jong-Hwa
Kim, Wonyong
Choi, Chang Hwan
author_facet Shin, Seung Yong
Park, Soo Jung
Kim, Young
Im, Jong Pil
Kim, Hyo Jong
Lee, Kang-Moon
Kim, Ji Won
Jung, Sung-Ae
Lee, Jun
Kang, Sang-Bum
Shin, Sung Jae
Kim, Eun Sun
Kim, You Sun
Kim, Tae Oh
Kim, Hyun-Soo
Park, Dong Il
Kim, Hyung Kil
Kim, Eun Soo
Kim, Young-Ho
Kim, Do Hyun
Teng, Dennis
Kim, Jong-Hwa
Kim, Wonyong
Choi, Chang Hwan
author_sort Shin, Seung Yong
collection PubMed
description BACKGROUND/AIMS: This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC). METHODS: A prospective, observational, multicenter study was conducted over 56 weeks in adult patients with moderately to severely active UC who received ADA. Clinical response, remission, and mucosal healing were assessed using the Mayo score. RESULTS: A total of 146 patients were enrolled from 17 academic hospitals. Clinical response rates were 52.1% and 37.7% and clinical remission rates were 24.0% and 22.0% at weeks 8 and 56, respectively. Mucosal healing rates were 39.0% and 30.1% at weeks 8 and 56, respectively. Prior use of anti-tumor necrosis factor-α (anti-TNF-α) did not affect clinical and endoscopic responses. The ADA drug level was significantly higher in patients with better outcomes at week 8 (P<0.05). In patients with lower endoscopic activity, higher body mass index, and higher serum albumin levels at baseline, the clinical response rate was higher at week 8. In patients with lower Mayo scores and C-reactive protein levels, clinical responses, and mucosal healing at week 8, the clinical response rate was higher at week 56. Serious adverse drug reactions were identified in 2.8% of patients. CONCLUSIONS: ADA is effective and safe for induction and maintenance in Korean patients with UC, regardless of prior anti-TNF-α therapy. The ADA drug level is associated with the efficacy of induction therapy. Patients with better short-term outcomes were predictive of those with an improved long-term response.
format Online
Article
Text
id pubmed-9344242
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Korean Association for the Study of Intestinal Diseases
record_format MEDLINE/PubMed
spelling pubmed-93442422022-08-02 Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study Shin, Seung Yong Park, Soo Jung Kim, Young Im, Jong Pil Kim, Hyo Jong Lee, Kang-Moon Kim, Ji Won Jung, Sung-Ae Lee, Jun Kang, Sang-Bum Shin, Sung Jae Kim, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Park, Dong Il Kim, Hyung Kil Kim, Eun Soo Kim, Young-Ho Kim, Do Hyun Teng, Dennis Kim, Jong-Hwa Kim, Wonyong Choi, Chang Hwan Intest Res Original Article BACKGROUND/AIMS: This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC). METHODS: A prospective, observational, multicenter study was conducted over 56 weeks in adult patients with moderately to severely active UC who received ADA. Clinical response, remission, and mucosal healing were assessed using the Mayo score. RESULTS: A total of 146 patients were enrolled from 17 academic hospitals. Clinical response rates were 52.1% and 37.7% and clinical remission rates were 24.0% and 22.0% at weeks 8 and 56, respectively. Mucosal healing rates were 39.0% and 30.1% at weeks 8 and 56, respectively. Prior use of anti-tumor necrosis factor-α (anti-TNF-α) did not affect clinical and endoscopic responses. The ADA drug level was significantly higher in patients with better outcomes at week 8 (P<0.05). In patients with lower endoscopic activity, higher body mass index, and higher serum albumin levels at baseline, the clinical response rate was higher at week 8. In patients with lower Mayo scores and C-reactive protein levels, clinical responses, and mucosal healing at week 8, the clinical response rate was higher at week 56. Serious adverse drug reactions were identified in 2.8% of patients. CONCLUSIONS: ADA is effective and safe for induction and maintenance in Korean patients with UC, regardless of prior anti-TNF-α therapy. The ADA drug level is associated with the efficacy of induction therapy. Patients with better short-term outcomes were predictive of those with an improved long-term response. Korean Association for the Study of Intestinal Diseases 2022-07 2021-07-23 /pmc/articles/PMC9344242/ /pubmed/34289648 http://dx.doi.org/10.5217/ir.2021.00049 Text en © Copyright 2022. Korean Association for the Study of Intestinal Diseases. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Shin, Seung Yong
Park, Soo Jung
Kim, Young
Im, Jong Pil
Kim, Hyo Jong
Lee, Kang-Moon
Kim, Ji Won
Jung, Sung-Ae
Lee, Jun
Kang, Sang-Bum
Shin, Sung Jae
Kim, Eun Sun
Kim, You Sun
Kim, Tae Oh
Kim, Hyun-Soo
Park, Dong Il
Kim, Hyung Kil
Kim, Eun Soo
Kim, Young-Ho
Kim, Do Hyun
Teng, Dennis
Kim, Jong-Hwa
Kim, Wonyong
Choi, Chang Hwan
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
title Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
title_full Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
title_fullStr Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
title_full_unstemmed Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
title_short Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
title_sort clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a kasid prospective multicenter cohort study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344242/
https://www.ncbi.nlm.nih.gov/pubmed/34289648
http://dx.doi.org/10.5217/ir.2021.00049
work_keys_str_mv AT shinseungyong clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT parksoojung clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT kimyoung clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT imjongpil clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT kimhyojong clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT leekangmoon clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT kimjiwon clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT jungsungae clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT leejun clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT kangsangbum clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT shinsungjae clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT kimeunsun clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT kimyousun clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT kimtaeoh clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT kimhyunsoo clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT parkdongil clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT kimhyungkil clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT kimeunsoo clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT kimyoungho clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT kimdohyun clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT tengdennis clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT kimjonghwa clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT kimwonyong clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy
AT choichanghwan clinicaloutcomesandpredictorsofresponseforadalimumabinpatientswithmoderatelytoseverelyactiveulcerativecolitisakasidprospectivemulticentercohortstudy